Substance / Medication

Lifitegrast

Overview

Active Ingredient
lifitegrast
RxNorm CUI
1801820

Indications

® Xiidra(lifitegrast ophthalmic solution) 5% is indicated for the treatment of the signs and symptoms of dry eye disease (DED).

Labeler: Novartis Pharmaceuticals CorporationUpdated: 2025-08-18T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

[see Adverse Reactions (6.2)] Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients in the formulation.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

No related conditions have been mapped yet. Condition-intervention linkages are derived from SNOMED CT relationships and will expand as the knowledge graph grows.

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Safety and tolerability of lifitegrast ophthalmic solution 5.0%: Pooled analysis of five randomized controlled trials in dry eye disease.
Nichols Kelly K, Donnenfeld Eric D, Karpecki Paul M et al. · Eur J Ophthalmol · 2019
PMID: 30112930TrialFull text (PMC)
Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3).
Holland Edward J, Luchs Jodi, Karpecki Paul M et al. · Ophthalmology · 2017
PMID: 28079022Trial
Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.
Tauber Joseph, Karpecki Paul, Latkany Robert et al. · Ophthalmology · 2015
PMID: 26365210Trial
Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study.
Sheppard John D, Torkildsen Gail L, Lonsdale John D et al. · Ophthalmology · 2014
PMID: 24289915Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Lifitegrast (substance)
SNOMED CT
720489009
UMLS CUI
C3713860
RxNorm CUI
1801820
Labeler
Novartis Pharmaceuticals Corporation

Clinical Data

This intervention maps to 0 entities in the Ltrl knowledge graph.

0
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.